Donor-derived hematopoietic stem cells in organ transplantation: Technical aspects and hurdles yet to be cleared

Transplantation

Volumn 75, Issue 9 SUPPL., 2003, Pages

  Hervé, Patrick ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACCREDITATION; ADOPTIVE IMMUNOTHERAPY; BLOOD; BONE MARROW; CELL SELECTION; CELL SEPARATION; CHIMERA; CONFERENCE PAPER; CYTAPHERESIS; ERYTHROCYTE; EUROPE; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; ILIAC CREST; IMMUNOLOGICAL TOLERANCE; LIVING DONOR; NONHUMAN; ORGAN TRANSPLANTATION; PLACENTA CIRCULATION; PRIORITY JOURNAL; QUALITY CONTROL; STEM CELL MOBILIZATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VERTEBRA BODY;

EID: 0038631824     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000067954.60639.9c     Document Type: Conference Paper

References (26)

1. Monaco AP, Clark AW, Wood ML, et al. Possible active enhancement of a human cadaver renal allograft with antilymphocytic serum (ALS) and donor bone marrow: Case report of an initial attempt. Surgery 1976; 79: 384.
2. Cianco G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001; 71: 827.
3. Garcia-Morales R, Carreno M, Mathew J, et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998; 65: 956.
4. Ricordi C, Karatzas T, Nery J, et al. High-dose donor bone marrow infusions to enhance allograft survival. Transplantation 1997; 63: 7.
5. De Pauw L, Abramowicz D, Donckier V, et al. Isolation and infusion of donor CD 34+ bone marrow cells in cadaver kidney transplantation. Nephrol Dial Transplant 1998; 1: 34.
6. Marshak DR, Gottlieb D, Gardner R. Stem cell biology. In: Marshak DR, Gottlieb D, Gardner R, eds. Stem cell biology. New York, Cold Spring Harbor Lab Press 2001, p 1.
7. Amos TA, Gordon MY. Sources of human hematopoietic stem cells for transplantation: A review. Cell Transplant 1995; 4: 547.
8. Donovan PJ, Gearhart J. The end of the beginning for pluripotent stem cells. Nature 2001; 414: 92.
9. Hervé P, Charbord P. Origin and techniques of haematopoietic stem cell collection. In: Hervé P, Rifle G, Vuitton DA, et al., eds. Organ transplantation and tissue grafting. London, Libbey/Inserm 1996, p 1105.
10. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51: 70.
11. Rybka WB, Fontes PA, Rao AB, et al. Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation. Transplantation 1995; 59: 871.
12. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413.
13. Bellavita P, Celega E, Poma R. Comparison of performance of six different cell separators in collecting peripheral blood mononuclear cells. Transfus Sci 1997; 18: 215.
14. Goldberg SL, Mangan KF, Klumpp TR, et al. Complications of peripheral blood stem cell harvesting: Review of 554 PBSC leukaphereses. J Hematother 1995; 4: 85.
15. Hildebrandt M, Serke S, Meyer O, et al. Immunomagnetic selection of CD 34+ cells: Factors influencing component purity and yield. Transfusion 2000; 40: 504.
16. Bensinger WI, Berenson RJ, Andrews RG, et al. Positive selection of hematopoietic progenitors from marrow and peripheral blood for transplantation. J Clin Apheresis 1990; 5: 74.
17. O'Donnell PV, Myers B, Edwards J, et al. CD 34 selection using three immunoselection devices: Comparison of T-cell depleted allografts. Cytotherapy 2001; 3: 483.
18. Joint Accreditation Committee of ISHAGE-Europe. Standards for blood and marrow progenitor cell processing, collection and transplantation. Cytotherapy 2000; 2: 225.
19. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD 34+ cell determination by flow cytometry. J Hematother 1996; 5: 213.
20. Hervé P, Tiberghien P. The emergence of cell therapy in France: Public health, regulations and other controversial issues. Hematol Cell Ther 1997; 39: 189.
21. Reisner Y, Martelli MF. Stem cell escalation enables HLA disparate haematopoietic transplants in leukaemia patients. Immunol Today 1999;20:343.
22. Schmitz N, Barrett J. Optimizing engraftment: Source and dose of stem cells. Semin Hematol 2002; 39: 3.
23. Douay L. Experimental culture conditions are critical for ex-vivo expansion of hematopoietic cells. J Hematother Stem Cell Res 2001; 10: 341.
24. Aglietta M, Bertolini F, Carlo-Stella C, et al. Ex-vivo expansion of hematopoietic cells and their clinical use. Haematologica 1998; 83: 824.
25. Salama AD, Remuzzi G, Harmon WE, et al. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001; 108: 943.
26. First Beaune Seminar in Transplant Research Proceedings. Dendritic cells in organ transplantation: Second signal blockade by monoclonal antibodies. Transplantation 2002; 73(suppl): S1.